METHOD FOR PHOTODYNAMIC THERAPY OF CERVICAL AND VULVAR NEOPLASMS UNDER THE CONTROL OF JOINT VIDEO AND SPECTRAL FLUORESCENT DIAGNOSTICS APPLYING CHLORIN SERIES PHOTOSENSITISERS Russian patent published in 2022 - IPC A61N5/06 A61K31/409 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to gynaecological oncology, and can be used for photodynamic therapy of human cervical and vulvar neoplasms. The method includes intravenous drip administration of a chlorin series photosensitiser: photolon, fotoran, or fotoditazin at a concentration of 0.8 to 1 mg/kg with 3-hour exposure of the photosensitiser. Light exposure is conducted by a laser emission source with a wavelength of 660 nm, with a power density of 0.3 to 0.5 W/cm² on the surface of the pathologically altered biological tissues, and a light energy density of 200 to 300 J/cm², prior to and after the photodynamic therapy; joint video fluorescence visualisation of the boundaries of the neoplasms and spectral- fluorescent diagnostics are performed. During video fluorescence visualisation, the fluorescence index is determined in the examined area by calculating the average value of pixel intensity of the image acquired from the infrared camera in the area isolated by the diagnostic cursor and normalising for the parameters of the infrared camera. The average value of pixel intensity of the image in the red channel of the colour camera in the area isolated by the diagnostic cursor is then calculated and normalised for the parameters of the colour camera, the first value is then normalised for the second. During spectral fluorescence diagnostics, the fluorescence index is calculated as the ratio of the area under the chlorin e6 fluorescence spectrum to the area under the spectrum of backscattered laser emission by the formula FI=I_700-800/I_650-670, wherein FI is the fluorescence index of the biological tissue, rel. U, I _700-800 is the area under the chlorin e6 fluorescence spectrum, I_650-670 is the area under the spectrum of backscattered laser emission, and the light effect is ended when the fluorescence indices are reduced by 60 to 80% after the photodynamic therapy.

EFFECT: possibility of visualising the boundaries of neoplasms, evaluating the degree of accumulation and the level of photobleaching of the chlorin series photosensitiser in the pathologically altered tissues prior to and after light exposure of the sensitised tissues, leading to the reduction in side effects and prevented continued progression of the disease.

1 cl, 4 dwg, 2 ex